The biology of NKT cells

Annual Review of Immunology

Volumn 25, Issue , 2007, Pages 297-336

  Bendelac, Albert ^a   Savage, Paul B ^b   Teyton, Luc ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b Brigham Young University   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

proteobacteria; Antigen presentation; CD1d; Ehrlichia; Glycolipid; Innate immunity; Lymphocyte development; Natural killer T cell; Salmonella; Sphingomonas

Indexed keywords

CD1D ANTIGEN; GLYCOSIDASE;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; CELL DIFFERENTIATION; ENDOSOME; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; LIPIDOSIS; LYSOSOME; MOLECULAR RECOGNITION; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; THYMUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; ANTIGENS, CD1; AUTOANTIGENS; BACTERIAL VACCINES; CD40 LIGAND; CHEMOKINES; DENDRITIC CELLS; GLOBOSIDES; GLUCOSYLCERAMIDES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TH1 CELLS; TH2 CELLS; TRIHEXOSYLCERAMIDES;

EID: 34247842744     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.25.022106.141711     Document Type: Review

References (250)

1. Sumida T, Takei I, Taniguchi M. 1984. Activation of acceptor-suppressor hybridoma with antigen specific suppressor T cell factor of two-chain type: requirement of the antigen-and the I-J-restricting specificity. J. Immunol. 133:1131-36
2. Sumida T, Taniguchi M. 1985. Novel mechanisms of specific suppression of antihapten antibody response mediated by monoclonal antihapten antibody. J. Immunol. 134:3675-81
3. Imai K, Kanno M, Kimoto H, Shigemoto T, Yamamoto S, Taniguchi M. 1986. Sequence and expression of transcripts of the T-cell antigen receptor α-chain gene in a functional, antigen-specific suppressor-T cell hybridoma. Proc. Natl. Acad. Sci. USA 83:8708-12
4. + T cell antigen receptor a chain expanded in unprimed mice. Proc. Natl. Acad. Sci. USA 87:5248-52
5. + T cell antigen receptor a chain in mice. Proc. Natl. Acad. Sci. USA 88:7518-22
6. Budd RC, Miescher GC, Howe RC, Lees RK, Bron C, Macdonald HR. 1987. Developmentally regulated expression of T cell receptor beta chain variable domains in immature thymocytes. J. Exp. Med. 166:577
7. Fowlkes BJ, Kruisbeek AM, Ton-That H, Weston MA, Coligan JE, et al. 1987. A novel population of T-cell receptor ab-bearing thymocytes which predominantly expresses a single Vβ8 gene family. Nature 329:251-55
8. - α/β T cells demonstrates preferential use of several Vβ genes and an invariant TCR α chain. J. Exp. Med. 178:1-16
9. - T cells. J. Exp. Med. 180:1171-76
10. + T cells acquire specific lymphokine secretion potentials during thymic maturation. Nature 353:68-71
11. Bendelac A, Matzinger P, Seder RA, Paul WE, Schwartz RH. 1992. Activation events during thymic selection. J. Exp. Med. 175:731-42
12. + T cell subsets: a subset (Thy0) that secretes diverse cytokines and overexpresses the Vβ8 T cell receptor gene family. J. Exp. Med. 176:269-74
13. - single-positive thymocyte subpopulation that expresses a highly skewed T cell antigen receptor family. Proc. Natl. Acad. Sci. USA 89:6506-10
14. - T cells in mice and humans. J. Exp. Med. 180:1097-106
15. - T cells. J. Exp. Med. 186:109-20
16. + thymocytes selected by MHC class I molecules. Science 263:1774-78
17. + T lymphocytes. Science 268:863-65
18. + T cells by CD1-expressing cortical thymocytes. J. Exp. Med. 182:2091-96
19. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L, Bendelac A. 2001. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J. Exp. Med. 193:893-904
20. + T cells in MHC class II-deficient mice. J. Exp. Med. 182:993-1004
21. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. 1997. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 278:1626-29
22. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, et al. 1998. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521-28
23. Mattner J, DeBord KL, Ismail N, Goff RD, Cantu C, et al. 2005. Both exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525-29
24. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, et al. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434:520-25
25. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. 2005. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35:1692-701
26. Zhou D, Mattner J, Cantu C, Schrantz N, Yin N, et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306:1786-89
27. Chiu YH, Jayawardena J, Weiss A, Lee D, Park SH, et al. 1999. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J. Exp. Med. 189:103-10
28. Eberl G, Lees R, Smiley ST, Taniguchi M, Grusby MJ, MacDonald HR. 1999. Tissue-specific segregation of CD1d-dependent and CD1d-independent NKT cells. J. Immunol. 162:6410-19
29. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. 2004. NKT cells: What's in a name? Nat. Rev. Immunol. 4:231-37
30. + NKT cells patrolling liver sinusoids. PLoS Biol. 3:e113
31. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A. 2002. A thymic precursor to the NKT cell lineage. Science 296:553-55
32. McNab FW, Berzins SP, Pellicci DG, Kyparissoudis K, Field K, et al. 2005. The influence of CD1d in postselection NKT cell maturation and homeostasis. J. Immunol. 175:3762-68
33. Esteban LM, Tsoutsman T, Jordan MA, Roach D, Poulton LD, et al. 2003. Genetic control of NKT cell numbers maps to major diabetes and lupus loci. J. Immunol. 171:2873-78
34. Rocha-Campos AC, Melici R, Zhu R, Deruytter N, Damotte D, et al. 2006. Genetic and functional analysis of the Nkt1 locus using congenic NOD mice: improved Vα14-NKT cell performance but failure to protect against type 1 diabetes. Diabetes 55:1163-70
35. + T cells that promptly produce interleukin-4. Proc. Natl. Acad. Sci. USA 92:11931-34
36. +-like thymocytes in the NOD mouse. Eur. J. Immunol. 26:2989-98
37. - T cell deficiency and IDDM in NOD/Lt mice. Diabetes 46:572-82
38. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. 2002. Testing the NKT cell hypothesis of human IDDM pathogenesis. J. Clin. Invest. 110:793-800
39. Liu Y, Goff RD, Zhou D, Mattner J, Sullivan BA, et al. 2006. A modified α-galactosyl ceramide for staining and stimulating natural killer T cells. J. Immunol. Methods 312:34-39
40. Matsuura A, Kinebuchi M, Chen HZ, Katabami S, Shimizu T, et al. 2000. NKT cells in the rat: organ-specific distribution of NK T cells expressing distinct Vα14 chains. J. Immunol. 164:3140-48
41. Pyz E, Naidenko O, Miyake S, Yamamura T, Berberich I, et al. 2006. The complementarity determining region 2 of BV8S2 (Vβ8.2) contributes to antigen recognition by rat invariant NKT cell TCR. J. Immunol. 176:7447-55
42. Van Rhijn I, Koets AP, Im JS, Piebes D, Reddington F, et al. 2006. The bovine CD1 family contains group 1 CD1 proteins, but no functional CD1d. J. Immunol. 176:4888-93
43. Tangri S, Brossay L, Burdin N, Lee DJ, Corr M, Kronenberg M. 1998. Presentation of peptide antigens by mouse CD1 requires endosomal localization and protein antigen processing. Proc. Natl. Acad. Sci. USA 95:14314-49
44. Brigl M, Brenner MB. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22:817-90
45. De Silva AD, Park JJ, Matsuki N, Stanic AK, Brutkiewicz RR, et al. 2 002. Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J. Immunol. 168:723-33
46. Joyce S, Woods AS, Yewdell JW, Bennink JR, Silva ADD, et al. 1998. Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 279:1541-44
47. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. 1995. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7:529-34
48. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, et al. 1995. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 38:2176-87
49. Yamaguchi Y, Motoki K, Ueno H, Maeda K, Kobayashi E, et al. 1996. Enhancing effects of (2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N- hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol. Res. 8:399-407
50. Sidobre S, Naidenko OV, Sim BC, Gascoigne NR, Garcia KC, Kronenberg M. 2002. The Vα14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J. Immunol. 169:1340-48
51. Cantu C, Benlagha K, Savage PB, Bendelac A, Teyton L. 2003. The paradox of immune molecular recognition of α-galactosylceramide: low affinity, low specificity for CD1d, high affinity for αβ TCRs. J. Immunol. 170:4673-82
52. Gadola SD, Koch M, Marles-Wright J, Lissin NM, Shepherd D, et al. 2006. Structure and binding kinetics of three different human CD1d-α- galactosylceramide-specific T cell receptors. J. Exp. Med. 203:699-710
53. Kawasaki S, Moriguchi R, Sekiya K, Nakai T, Ono E, et al. 1994. The cell envelope structure of the lipopolysaccharide-lacking Gram-negative bacterium Sphingomonas paucimobilis. J. Bacteriol. 176:284-90
54. Kawahara K, Moll H, Knirel YA, Seydel U, Zahringer U. 2000. Structural analysis of two glycosphingolipids from the lipopolysaccharide-lacking bacterium Sphingomonas capsulata. Eur. J. Biochem. 267:1837-46
55. Wu D, Xing GW, Poles MA, Horowitz A, Kinjo Y, et al. 2005. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc. Natl. Acad. Sci. USA 102:1351-56
56. Prigozy TI, Naidenko O, Qasba P, Elewaut D, Brossay L, et al. 2001. Glycolipid antigen processing for presentation by CD1d molecules. Science 291:664-67
57. Zhou XT, Forestier C, Goff RD, Li C, Teyton L, et al. 2002. Synthesis and NKT cell stimulating properties of fluorophore- and biotin-appended 6″-amino-6″-deoxygalactosylceramides. Org. Lett. 4:1267-70
58. Dieckmann R, Graeber I, Kaesler I, Szewzyk U, von Dohren H. 2005. Rapid screening and dereplication of bacterial isolates from marine sponges of the sula ridge by intact-cell-MALDI-TOF mass spectrometry (ICM-MS). Appl. Microbiol. Biotechnol. 67:539-48
59. Park SH, Roark JH, Bendelac A. 1998. Tissue specific recognition of mouse CD1 molecules. J. Immunol. 160:3128-34
60. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4:1230-37
61. + NKT cells in germ-free mice. Eur. J. Immunol. 30:620-25
62. Schumann J, Mycko MP, Dellabona P, Casorati G, MacDonald HR. 2006. Cutting edge: influence of the TCR Vβ domain on the selection of semi-invariant NKT cells by endogenous ligands. J. Immunol. 176:2064-68
63. Xia C, Yao Q, Schumann J, Rossy E, Chen W, et al. 2006. Synthesis and biological evaluation of α-galactosylceramide (KRN7000) and isoglobotrihexosylceramide (iGb3). Bioorg. Med. Chem. Lett. 16:2195-99
64. Chiu YH, Park SH, Benlagha K, Forestier C, Jayawardena-Wolf J, et al. 2002. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat. Immunol. 3:55-60
65. Zhou D, Cantu C, Sagiv Y, Schrantz N, Kulkarni AB, et al. 2004. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303:523-27
66. Kang SJ, Cresswell P. 2004. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 5:175-81
67. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, et al. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7:978-86
68. Kumar H, Belperron A, Barthold SW, Bockenstedt LK. 2000. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi. J. Immunol. 165:4797-801
69. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, et al. 2004. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl. Acad. Sci. USA 101:10685-90
70. Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB. 1999. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J. Exp. Med. 189:1973-80
71. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, et al. 2000. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211-21
72. Agea E, Russano A, Bistoni O, Mannucci R, Nicoletti I, et al. 2005. Human CD1-restricted T cell recognition of lipids from pollens. J. Exp. Med. 202:295-308
73. Russano AM, Agea E, Corazzi L, Postle AD, De Libero G, et al. 2006. Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted γδ T cells. J. Allergy Clin. Immunol. 117:1178-84
74. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. 2003. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198:173-81
75. Parekh VV, Singh AK, Wilson MT, Olivares-Villagomez D, Bezbradica JS, et al. 2004. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173:3693-706
76. Stanic AK, De Silva AD, Park JJ, Sriram V, Ichikawa S, et al. 2003. Defective presentation of the CD1d1-restricted natural Vα14Jα18 NKT lymphocyte antigen caused by β-D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. USA 100:1849-54
77. Zajonc DM, Cantu C, Mattner J, Zhou D, Savage PB, et al. 2005. Structure and function of a potent agonist for the semi-invariant NKT cell receptor. Nat. Immunol. 6:810-18
78. Wu D, Zajonc DM, Fujio M, Sullivan BA, Kinjo Y, et al. 2006. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc. Natl. Acad. Sci. USA 103:3972-77
79. Zajonc DM, Maricic I, Wu D, Halder R, Roy K, et al. 2005. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202:1517-26
80. Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, et al. 2005. The crystal structure of human CD1d with and without α-galactosylceramide. Nat. Immunol. 6:819-26
81. Kjer-Nielsen L, Borg NA, Pellicci DG, Beddoe T, Kostenko L, et al. 2006. A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition. J. Exp. Med. 203:661-73
82. Roark JH, Park SH, Jayawardena J, Kavita U, Shannon M, Bendelac A. 1998. CD1.1 expression by mouse antigen presenting cells and marginal zone B cells. J. Immunol. 160:3121-27
83. Brossay L, Jullien D, Cardell S, Sydora BC, Burdin N, et al. 1997. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J. Immunol. 159:1216-24
84. Skold M, Xiong X, Illarionov PA, Besra GS, Behar SM. 2005. Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation. J. Immunol. 175:3584-93
85. de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, et al. 2004. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J. Immunol. 173:1417-25
86. Wei DG, Lee H, Park SH, Beaudoin L, Teyton L, et al. 2005. Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. J. Exp. Med. 202:239-48
87. Busshoff U, Hein A, Iglesias A, Dorries R, Regnier-Vigouroux A. 2001. CD1 expression is differentially regulated by microglia, macrophages and T cells in the central nervous system upon inflammation and demyelination. J. Neuroimmunol. 113:220-30
88. Kang SJ, Cresswell P. 2002. Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain. J. Biol. Chem. 277:44838-44
89. Jayawardena-Wolf J, Benlagha K, Chiu YH, Mehr R, Bendelac A. 2001. CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain. Immunity 15:897-908
90. Kang SJ, Cresswell P. 2002. Regulation of intracellular trafficking of human CD1d by association with MHC class II molecules. EMBO J. 21:1650-60
91. Roberts TJ, Sriram V, Spence PM, Gui M, Hayakawa K, et al. 2002. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J. Immunol. 168:5409-14
92. Lawton AP, Prigozy TI, Brossay L, Pei B, Khurana A, et al. 2005. The mouse CD1d cytoplasmic tail mediates CD1d trafficking and antigen presentation by adaptor protein 3-dependent and -independent mechanisms. J. Immunol. 174:3179-86
93. Cernadas M, Sugita M, van der Wel N, Cao X, Gumperz JE, et al. 2003. Lysosomal localization of murine CD1d mediated by AP-3 is necessary for NK T cell development. J. Immunol. 171:4149-55
94. Sugita M, Cao X, Watts GF, Rogers RA, Bonifacino JS, Brenner MB. 2002. Failure of trafficking and antigen presentation bv CD1 in AP-3-deficient cells. Immunity 16:697-706
95. Sanchez DJ, Gumperz JE, Ganem D. 2005. Regulation of CD1d expression and function by a herpesvirus infection. J. Clin. Invest. 115:1369-78
96. Yuan W, Dasgupta A, Cresswell P. 2006. Herpes simplex virus evades natural killer T cell recognition by suppressing CD1d recycling. Nat. Immunol. 7:835-42
97. van den Elzen P, Garg S, Leon L, Brigl M, Leadbetter EA, et al. 2005. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437:906-10
98. Prigozy TI, Sieling PA, Clemens D, Stewart PL, Behar SM, et al. 1997. The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules. Immunity 6:187-97
99. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, et al. 2004. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J. Clin. Invest. 113:701-8
100. Marks DL, Pagano RE. 2002. Endocytosis and sorting of glycosphingolipids in sphingolipid storage disease. Trends Cell Biol. 12:605-13
101. Gadola SD, Silk JD, Jeans A, Illarionov PA, Salio M, et al. 2006. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J. Exp. Med. 203:2293-303
102. Sagiv Y, Hudspeth K, Mattner J, Schrantz N, Stern RK, et al. 2006. Cutting edge: impaired glycosphingolipid trafficking and NKT cell development in mice lacking Niemann-Pick type C1 protein. J. Immunol. 177:26-30
103. Sandhoff K, Kolter T. 2003. Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R. Soc. London B Biol. Sci. 358:847-61
104. Moody DB, Briken V, Cheng TY, Roura-Mir C, Guy MR, et al. 2002. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat. Immunol. 3:435-42
105. Ernst WA, Maher J, Cho S, Niazi KR, Chatterjee D, et al. 1998. Molecular interaction of CD1b with lipoglycan antigens. Immunity 8:331-40
106. Cheng TY, Relloso M, Van Rhijn I, Young DC, Besra GS, et al. 2006. Role of lipid trimming and CD1 groove size in cellular antigen presentation. EMBO J. 25:2989-99
107. Gadola SD, Zaccai NR, Harlos K, Shepherd D, Castro-Palomino JC, et al. 2002. Structure of human CD1b with bound ligands at 2.3 Å, a maze for alkyl chains. Nat. Immunol. 3:721-26
108. Schuette CG, Pierstorff B, Huettler S, Sandhoff K. 2001. Sphingolipid activator proteins: proteins with complex functions in lipid degradation and skin biogenesis. Glycobiology 11:81-90R
109. Brozovic S, Nagaishi T, Yoshida M, Betz S, Salas A, et al. 2004. CD1d function is regulated by microsomal triglyceride transfer protein. Nat. Med. 10:535-39
110. Dougan SK, Salas A, Rava P, Agyemang A, Kaser A, et al. 2005. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J. Exp. Med. 202:529-39
111. de la Salle H, Mariotti S, Angenieux C, Gilleron M, Garcia-Alles LF, et al. 2005. Assistance of microbial glycolipid antigen processing by CD1e. Science 310:1321-24
112. Honey K, Benlagha K, Beers C, Forbush K, Teyton L, et al. 2002. Thymocyte expression of cathepsin L is essential for NKT cell development. Nat. Immunol. 3:1069-74
113. + NK T cells in the early stages of embryogenesis. Proc. Natl. Acad. Sci. USA 93:6516-20
114. + T cells. Eur. J. Immunol. 27:1576-79
115. Bendelac A, Hunziker RD, Lantz O. 1996. Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells. J. Exp. Med. 184:1285-93
116. + T cells with a transgenic variant TCR. J. Immunol. 165:168-74
117. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. 2000. In vivo identification of glycolipid antigen specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191:1895-903
118. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, et al. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741-54
119. Karadimitris A, Gadola S, Altamirano M, Brown D, Woolfson A, et al. 2001. From the cover: human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc. Natl. Acad. Sci. USA 98:3294-98
120. Benlagha K, Wei DG, Veiga J, Teyton L, Bendelac A. 2005. Characterization of the early stages in thymic NKT cell development. J. Exp. Med. 202:485-92
121. Gapin L, Matsuda JL, Surh CD, Kronenberg M. 2001. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat. Immunol. 2:971-78
122. + stage of thymic ontogeny. Proc. Natl. Acad. Sci. USA 102:5114-19
123. Egawa T, Eberl G, Taniuchi I, Benlagha K, Geissmann F, et al. 2005. Genetic evidence supporting selection of the Vα14i NKT cell lineage from double-positive thymocyte precursors. Immunity 22:705-16
124. + CD1d-dependent precursor stage. J. Exp. Med. 195:835-44
125. Benlagha K, Bendelac A. 2000. CD1d-restricted mouse Vα14 and human Vα24 T cells: lymphocytes of innate immunity. Semin. Immunol. 12:537-42
126. Gumperz JE, Miyake S, Yamamura T, Brenner MB. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195:625-36
127. Lee PT, Benlagha K, Teyton L, Bendelac A. 2002. Distinct functional lineages of human vα24 natural killer T cells. J. Exp. Med. 195:637-41
128. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, et al. 2005. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202:1279-88
129. Berzins SP, Cochrane AD, Pellicci DG, Smyth MJ, Godfrey DI. 2005. Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur. J. Immunol. 35:1399-407
130. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, et al. 2003. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J. Exp. Med. 198:1069-76
131. + T cells. J. Exp. Med. 187:2109-14
132. Exley M, Porcelli S, Furman M, Garcia J, Balk S. 1998. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24 JαQ T cell receptor α chains. J. Exp. Med. 188:867-76
133. Ikarashi Y, Mikami R, Bendelac A, Terme M, Chaput N, et al. 2001. Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition. Critical role for β7 in CD1d-dependent NKT cell interferon gamma production. J. Exp. Med. 194:1179-86
134. + TCRαβ cell development. Eur. J. Immunol. 29:1966-71
135. Wei DG, Curran SA, Savage PB, Teyton L, Bendelac A. 2006. Mechanisms imposing the Vβ bias of Vα14 natural killer T cells and consequences for microbial glycolipid recognition. J. Exp. Med. 203:1197-207
136. Chun T, Page MJ, Gapin L, Matsuda JL, Xu H, et al. 2003. CD1d-expressing dendritic cells but not thymic epithelial cells can mediate negative selection of NKT cells. J. Exp. Med. 197:907-18
137. + T cells. J. Immunol. 171:4105-12
138. Voyle RB, Beermann F, Lees RK, Schumann J, Zimmer J, et al. 2003. Ligand-dependent inhibition of CD1d-restricted NKT cell development in mice transgenic for the activating receptor Ly49D. J. Exp. Med. 197:919-25
139. Schumann J, Pittoni P, Tonti E, Macdonald HR, Dellabona P, Casorati G. 2005. Targeted expression of human CD1d in transgenic mice reveals independent roles for thymocytes and thymic APCs in positive and negative selection of Vα14i NKT cells. J. Immunol. 175:7303-10
140. + cells. J. Immunol. 164:2412-18
141. Zimmer MI, Colmone A, Felio K, Xu H, Ma A, Wang CR. 2006. A cell-type specific CD1d expression program modulates invariant NKT cell development and function. J. Immunol. 176:1421-30
142. Gadue P, Morton N, Stein PL. 1999. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J. Exp. Med. 190:1189-96
143. Eberl G, Lowin-Kropf B, MacDonald HR. 1999. Cutting edge: NKT cell development is selectively impaired in Fyn-deficient mice. J. Immunol. 163:4091-94
144. Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, et al. 2005. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J. Exp. Med. 201:695-701
145. Nichols KE, Hom J, Gong SY, Ganguly A, Ma CS, et al. 2005. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat. Med. 11(3):340-45
146. Chung B, Aoukaty A, Dutz J, Terhorst C, Tan R. 2005. Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J. Immunol. 174:3153-57
147. Sayos J, Wu C, Morra M, Wang N, Zhang X, et al. 1998. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the coreceptor SLAM. Nature 395:462-69
148. Chan B, Lanyi A, Song HK, Griesbach J, Simarro-Grande M, et al. 2003. SAP couples Fyn to SLAM immune receptors. Nat. Cell Biol. 5:155-60
149. Latour S, Gish G, Helgason CD, Humphries RK, Pawson T, Veillette A. 2001. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat. Immunol. 2:681-90
150. Latour S, Roncagalli R, Chen R, Bakinowski M, Shi X, et al. 2003. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signaling in immune regulation. Nat. Cell Biol. 5:149-54
151. Veillette A, Latour S. 2003. The SLAM family of immune-cell receptors. Curr. Opin. Immunol. 15:277-85
152. Gadue P, Yin L, Jain S, Stein PL. 2004. Restoration of NK T cell development in fyn-mutant mice by a TCR reveals a requirement for Fyn during early NKT cell ontogeny. J. Immunol. 172:6093-100
153. Borowski C, Bendelac A. 2005. Signaling for NKT cell development: the SAP-Fyn connection. J. Exp. Med. 201:833-36
154. Stanic AK, Bezbradica JS, Park JJ, Matsuki N, Mora AL, et al. 2004. NF-κB controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J. Immunol. 172:2265-73
155. Sivakumar V, Hammond KJ, Howells N, Pfeffer K, Weih F. 2003. Differential requirement for Rel/nuclear factor κB family members in natural killer T cell development. J. Exp. Med. 197:1613-21
156. H2 differentiation and PKC-θ-mediated activation of NF-κB1. Immunity 21:693-706
157. + regulatory and natural killer-like T cells on signals leading to NF-κB activation. Proc. Natl. Acad. Sci. USA 101:4566-71
158. Stanic AK, Bezbradica JS, Park JJ, Van Kaer L, Boothby MR, Joyce S. 2004. Cutting edge: the ontogeny and function of Vα14Jα18 natural T lymphocytes require signal processing by protein kinase Cθ and NF-κB. J. Immunol. 172:4667-71
159. Wang N, Satoskar A, Faubion W, Howie D, Okamoto S, et al. 2004. The cell surface receptor SLAM controls T cell and macrophage functions. J. Exp. Med. 199:1255-64
160. Townsend MJ, Weinmann AS, Matsuda JL, Salomon R, Farnham PJ, et al. 2004. T-bet regulates the terminal maturation and homeostasis of NK and Vα14i NKT cells. Immunity 20:477-94
161. + T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6:1236-44
162. Matsuda JL, Zhang Q, Ndonye R, Richardson SK, Howell AR, Gapin L. 2006. T-bet concomitantly controls migration, survival, and effector functions during the development of Vα14/NKT cells. Blood 107:2797-805
163. + T cells. Immunity 25:79-91
164. + T cell lineages in mice deficient for the Tec kinases Itk and Rlk. Immunity 25:93-104
165. Li W, Kim MG, Gourley TS, McCarthy BP, Sant'Angelo DB, Chang CH. 2005. An alternate pathway for CD4 T cell development: thymocyte-expressed MHC class II selects a distinct T cell population. Immunity 23:375-86
166. Kunisaki Y, Tanaka Y, Sanui T, Inayoshi A, Noda M, et al. 2006. DOCK2 is required in T cell precursors for development of Vα14 NKT cells. J. Immunol. 176:4640-45
167. Williams KL, Zullo AJ, Kaplan MH, Brutkiewicz RR, Deppmann CD, et al. 2003. BATF transgenic mice reveal a role for activator protein-1 in NKT cell development. J. Immunol. 170:2417-26
168. Zullo AJ, Benlagha K, Bendelac A, Taparowsky E. 2007. Sensitivity of NKT cells to transgenic BATF defines a role for AP-1 in the expansion and maturation of NKT cells in the thymus. J. Immunol. 178:58-66
169. Elewaut D, Shaikh RB, Hammond KJ, De Winter H, Leishman AJ, et al. 2003. NIK-dependent RelB activation defines a unique signaling pathway for the development of Vα14i NKT cells. J. Exp. Med. 197:1623-33
170. Boehm T, Scheu S, Pfeffer K, Bleul CC. 2003. Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTβR. J. Exp. Med. 198:757-69
171. Iizuka K, Chaplin DD, Wang Y, Wu Q, Pegg LE, et al. 1999. Requirement for membrane lymphotoxin in natural killer cell development. Proc. Natl. Acad. Sci. USA 96:6336-40
172. Elewaut D, Brossay L, Santee SM, Naidenko OV, Burdin N, et al. 2000. Membrane lymphotoxin is required for the development of different subpopulations of NKT cells. J. Immunol. 165:671-79
173. Franki AS, Van Beneden K, Dewint P, Hammond KJ, Lambrecht S, et al. 2006. A unique lymphotoxin αβ-dependent pathway regulates thymic emigration of Vα14 invariant natural killer T cells. Proc. Natl. Acad. Sci. USA 103:9160-65
174. Bezbradica JS, Gordy LE, Stanic AK, Dragovic S, Hill T, et al. 2006. Granulocyte-macrophage colony-stimulating factor regulates effector differentiation of invariant natural killer T cells during thymic ontogeny. Immunity 25:487-97
175. +NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J. Immunol. 163:93-101
176. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121-28
177. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, et al. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163:4647-50
178. Eberl G, MacDonald HR. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30:985-92
179. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, et al. 2002. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195:617-24
180. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267-79
181. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199:1607-18
182. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, et al. 2004. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J. Clin. Invest. 114:1800-11
183. Parekh W, Wilson MT, Van Kaer L. 2005. iNKT-cell responses to glycolipids. Crit. Rev. Immunol. 25:183-213
184. Yoshimoto T, Paul WE. 1994. CD4pos NK1.1pos T cells promptly produced IL-4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179:1285-95
185. Miyamoto K, Miyake S, Yamamura T. 2 001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413:531-34
186. Oki S, Chiba A, Yamamura T, Miyake S. 2004. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113:1631-40
187. Eberl G, MacDonald HR. 1998. Rapid death and regeneration of NKT cells in anti-CD3 epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 9:345-53
188. Uldrich AP, Crowe NY, Kyparissoudis K, Pellicci DG, Zhan Y, et al. 2005. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175:3092-101
189. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, et al. 2005. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115:2572-83
190. Fujii S, Shimizu K, Kronenberg M, Steinman RM. 2002. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 3:867-74
191. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201:1503-17
192. Goff RD, Gao Y, Mattner J, Zhou D, Yin N, et al. 2004. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc. 126:13602-3
193. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, et al. 2005. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl. Acad. Sci. USA 102:3383-88
194. Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, et al. 2005. Distinct roles of dendritic cells and B cells in Vα14Jα18 natural T cell activation in vivo. J. Immunol. 174:4696-705
195. Cui J, Shin T, Kawano T, Sato H, Kondo E, et al. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623-26
196. Park SH, Kyin T, Bendelac A, Carnaud C. 2003. The contribution of NKT cells, NK cells, and other γ-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J. Immunol. 170:1197-201
197. Nieuwenhuis EE, Matsumoto T, Exley M, Schleipman RA, Glickman J, et al. 2002. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat. Med. 8:588-93
198. Muhlen KA, Schumann J, Wittke F, Stenger S, Van Rooijen N, et al. 2004. NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice. J. Immunol. 172:3034-41
199. Dieli F, Sireci G, Russo D, Taniguchi M, Ivanyi J, et al. 2000. Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction. J. Exp. Med. 192:1645-52
200. +NKT cells in lipopolysaccharide-induced lethal shock in mice. J. Immunol. 169:1426-32
201. Kaplan MM, Gershwin ME. 2005. Primary biliary cirrhosis. N. Engl. J. Med. 353:1261-73
202. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, et al. 2003. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38:1250-57
203. Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, et al. 2002. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123:1031-43
204. Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, et al. 1999. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 283:225-29
205. Molano A, Park SH, Chiu YH, Nosseir S, Bendelac A, Tsuji M. 2000. Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses. J. Immunol. 164:5005-9
206. Romero JF, Eberl G, MacDonald H, Corradin G. 2001. CD1d-restricted NK T cells are dispensable for specific antibody responses and protective immunity against liver stage malaria infection in mice. Parasite Immunol. 23:267-69
207. Mallevaey T, Zanetta JP, Faveeuw C, Fontaine J, Maes E, et al. 2006. Activation of invariant NKT cells by the helminth parasite Schistosoma mansoni. J. Immunol. 176:2476-85
208. Ilyinskii PO, Wang R, Balk SP, Exley MA. 2006. CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo. J. Virol. 80:7146-58
209. Huber S, Sartini D, Exley M. 2003. Role of CD1d in coxsackievirus B3-induced myocarditis. J. Immunol. 170:3147-53
210. Durante-Mangoni E, Wang R, Shaulov A, He Q, Nasser I, et al. 2004. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J. Immunol. 173:2159-66
211. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. 2003. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα14-Jα281 TCR. J. Immunol. 170:1430-34
212. Cornish AL, Keating R, Kyparissoudis K, Smyth MJ, Carbone FR, Godfrey DI. 2006. NKT cells are not critical for HSV-1 disease resolution. Immunol. Cell Biol. 84:13-19
213. Wilson SB, Kemt SC, Patton KT, Orban T, Jackson RA, et al. 1998. Extreme Th1 bias of invariant Vα24JαQ T cells in type I diabetes. Nature 391:177-81
214. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, et al. 2002. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109:131-40
215. Redondo MJ, Gottlieb PA, Motheral T, Mulgrew C, Rewers M, et al. 1999. Heterophile antimouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes 48:2166-70
216. Wang B, Geng YB, Wang CR. 2001. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 194:313-20
217. Shi FD, Flodstrom M, Balasa B, Kim SH, Van Gunst K, et al. 2001. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 98:6777-82
218. Bach JF, Bendelac A, Brenner MB, Cantor H, De Libero G, et al. 2004. The role of innate immunity in autoimmunity. J. Exp. Med. 200:1527-31
219. Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, et al. 1998. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188:1831-39
220. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, et al. 2001. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 7:1057-62
221. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, et al. 2001. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in nonobese diabetic mice. Nat. Med. 7:1052-56
222. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. 2002. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells. Immunity 17:725-36
223. Griseri T, Beaudoin L, Novak J, Mars LT, Lepault F, et al. 2005. Invariant NKT cells exacerbate type 1 diabetes induced by CD8 T cells. J. Immunol. 175:2091-101
224. 1 mice. J. Immunol. 175:763-70
225. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. 2003. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 112:1211-22
226. 2-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(1pr) nice: an example of disease regulation at the organ level. J. Immunol. 167:2985-90
227. Yang JQ, Chun T, Liu H, Hong S, Bui H, et al. 2004. CD1d deficiency exacerbates inflammatory dermatitis in MRL-1pr/1pr mice. Eur. J. Immunol. 34:1723-32
228. Yang JQ, Singh AK, Wilson MT, Satoh M, Stanic AK, et al. 2003. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J. Immunol. 171:2142-53
229. Singh AK, Yang JQ, Parekh W, Wei J, Wang CR, et al. 2005. The natural killer T cell ligand α-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur. J. Immunol. 35:1143-54
230. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, et al. 2001. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol. 167:4046-50
231. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, et al. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197:1667-76
232. + T cell lymphoma by natural killer T (NKT) cells. Proc. Natl. Acad. Sci. USA 99:8197-202
233. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, et al. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:661-68
234. Crowe NY, Smyth MJ, Godfrey DI. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119-27
235. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, et al. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-20
236. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, et al. 2005. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202:1627-33
237. Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Van Kaer L, Brutkiewicz RR. 2006. Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int. J. Cancer 118:3045-53
238. Lisbonne M, Diem S, de Castro Keller A, Lefort J, Araujo LM, et al. 2003. Cutting edge: invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. 171:1637-41
239. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, et al. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9:582-88
240. + natural killer T cells in bronchial asthma. N. Engl. J. Med. 354:1117-29
241. Thomas SY, Lilly CM, Luster AD. 2006. Invariant natural killer T cells in bronchial asthma. N. Engl. J. Med. 354:2613-16
242. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, et al. 2004. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199:417-22
243. + NKT cells and B-1 B cells. Trends Immunol. 25:441-49
244. Sonoda KH, Exley M, Snapper S, Balk SP, Stein-Streilein J. 1999. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190:1215-26
245. Palmer JL, Tulley JM, Kovacs EJ, Gamelli RL, Taniguchi M, Faunce DE. 2006. Injury-induced suppression of effector T cell immunity requires CD1d-positive APCs and CD1d-restricted NKT cells. J. Immunol. 177:92-99
246. Porcelli SA. 2005. Bird genes give new insights into the origins of lipid antigen presentation. Proc. Natl. Acad. Sci. USA 102:8399-400
247. + T lymphocytes. J. Immunol. 168:5514-20
248. Brigl M, van den Elzen P, Chen X, Meyers JH, Wu D, et al. 2006. Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors. J. Immunol. 176:3625-34
249. Zerrahn J, Held W, Raulet DH. 1997. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 88:627-36
250. Huseby ES, White J, Crawford F, Vass T, Becker D, et al. 2005. How the T cell repertoire becomes peptide and MHC specific. Cell 122:247-60